Looking at the universe of stocks we cover at Dividend Channel, on 2/25/16, Full Circle Capital Corp (FULL) will trade ex-dividend, for its monthly dividend of $0.035, payable on 3/15/16. As a percentage of FULL's recent stock price of $2.16, this dividend works out to approximately 1.62%, so look for shares of Full Circle Capital Corp to trade 1.62% lower — all else being equal — when FULL shares open for trading on 2/25/16.Below is a dividend history chart for FULL, showing historical dividends prior to the most recent $0.035 declared by Full Circle Capital Corp: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from FULL is likely to continue, and whether the current estimated yield of 19.45% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of FULL shares, versus its 200 day moving average: Looking at the chart above, FULL's low point in its 52 week range is $2.04 per share, with $4.69 as the 52 week high point — that compares with a last trade of $2.16. In Tuesday trading, Full Circle Capital Corp shares are currently off about 0.5% on the day.
HOST // Robert Powell
Retirement Planning Event
More from Stocks
Alibaba and Amarin Among Unanimous Strong Buy Stocks
You know a stock is doing well when the all market's best analysts are bullish.
Cheniere Energy's Party May Not Be Over Based on Its Charts
Traders might be late to the party, but a pullback from recent highs could offer a secondary entry point in the LNG name.
Market Evolution, China Trade, Copper Pricing, Apple Event: Market Recon
With the Mueller cloud removed from the most pro-business administration in recent U.S. history, the focus should simply be found in these two words...what now?
As Amazon's Growth Slows, Its Margin of Safety Has Become Razor Thin
Looking into the rear view mirror for Amazon will fail to show risks to growth ahead.
Biogen Announces $5 Billion Buyback Just Days After Stock Plunge
Biogen's board approves a share buyback program days after revealing a phase III trial of a promising Alzheimer's drug is being shelved.